M
Michael Hughes
Researcher at Royal Hallamshire Hospital
Publications - 615
Citations - 26328
Michael Hughes is an academic researcher from Royal Hallamshire Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 74, co-authored 531 publications receiving 24066 citations. Previous affiliations of Michael Hughes include Royal College of Physicians & St Thomas' Hospital.
Papers
More filters
Journal ArticleDOI
Neurodevelopment and In Utero Antiretroviral Exposure of HIV-Exposed Uninfected Infants
Paige L. Williams,Miguel Marino,Kathleen Malee,Susan B. Brogly,Michael Hughes,Lynne M. Mofenson +5 more
TL;DR: Mental and motor functioning scores were not lower for infants with in utero ARV exposure compared with no exposure, and continued evaluation of uninfected children with in Utero ARVs exposure for long-term adverse outcomes is important.
Journal ArticleDOI
Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients
Xiao-Jian Zhou,Lewis B. Sheiner,Richard T. D'Aquila,Michael Hughes,Michael Hughes,Martin S. Hirsch,Margaret A. Fischl,Victoria A. Johnson,Maureen Myers,Jean-Pierre Sommadossi +9 more
TL;DR: Large (>50%) intraindividual variability was associated with both ZDV and ddI pharmacokinetics, and individual cumulative area under the plasma drug level-time curve of the three drugs was calculated for the entire study period as a measure of drug exposure.
Journal ArticleDOI
Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women
Edward P. Acosta,Arlene Bardeguez,Carmen D. Zorrilla,Russell B. Van Dyke,Michael Hughes,Sharon Huang,Lisa Pompeo,Alice Stek,Jane Pitt,D. Heather Watts,Elizabeth Smith,Eleanor Jimenez,Lynne M. Mofenson +12 more
TL;DR: This is the first formal PK evaluation of a dual protease inhibitor regimen with HIV-infected pregnant women and results suggest that SQV-RTV at 800/100 mg b.i.d. appears to be a reasonable treatment option for this population.
Journal ArticleDOI
CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group
TL;DR: CD4 cell count is a weak surrogate endpoint, but has some value as an aid for screening treatments for drug development or preliminary regulatory approval, and other mechanisms of drug action not captured by initial change in CD4 cells are important.
Journal ArticleDOI
Estimation issues in clinical trials and overviews.
Stuart J. Pocock,Michael Hughes +1 more
TL;DR: This article examines a number of issues which affect the use and interpretation of conventional estimation methods and concludes that the emphasis on estimation methods is a powerful tool for encouraging larger sample sizes.